All three major indices are trading up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 93 points (0.5%) at 17,674 as of Wednesday, Oct. 28, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,445 issues advancing vs. 542 declining with 141 unchanged.

The Health Care sector currently sits up 2.1% versus the S&P 500, which is up 0.7%. Top gainers within the sector include

Boston Scientific

(

BSX

), up 7.8%,

GlaxoSmithKline

(

GSK

), up 4.3%,

Teva Pharmaceutical Industries

(

TEVA

), up 4.3%,

Express Scripts

(

ESRX

), up 2.9% and

Merck

(

MRK

), up 2.5%. On the negative front, top decliners within the sector include

Gilead

(

GILD

), down 2.7%,

CVS Health

(

CVS

), down 1.8% and

Regeneron Pharmaceuticals

(

REGN

), down 0.8%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3.

Abbott Laboratories

(

ABT

) is one of the companies pushing the Health Care sector higher today. As of noon trading, Abbott Laboratories is up $0.58 (1.3%) to $44.46 on light volume. Thus far, 2.4 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 7.6 million shares. The stock has ranged in price between $43.64-$44.50 after having opened the day at $43.96 as compared to the previous trading day's close of $43.88.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Abbott Laboratories manufactures and sells health care products worldwide. Abbott Laboratories has a market cap of $65.0 billion and is part of the health services industry. Shares are down 2.5% year-to-date as of the close of trading on Tuesday. Currently there are 12 analysts who rate Abbott Laboratories a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Recommends

TheStreet Ratings rates

Abbott Laboratories

as a

buy

. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, increase in stock price during the past year, impressive record of earnings per share growth and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full

Abbott Laboratories Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Eli Lilly and

(

LLY

) is up $1.88 (2.3%) to $82.80 on average volume. Thus far, 2.3 million shares of Eli Lilly and exchanged hands as compared to its average daily volume of 5.7 million shares. The stock has ranged in price between $80.39-$82.82 after having opened the day at $81.10 as compared to the previous trading day's close of $80.91.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. Eli Lilly and has a market cap of $87.7 billion and is part of the drugs industry. Shares are up 17.3% year-to-date as of the close of trading on Tuesday. Currently there are 7 analysts who rate Eli Lilly and a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates

Eli Lilly and

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, solid stock price performance, growth in earnings per share and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

Eli Lilly and Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Valeant Pharmaceuticals International

(

VRX

) is up $6.77 (6.2%) to $116.31 on heavy volume. Thus far, 6.1 million shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 7.2 million shares. The stock has ranged in price between $108.20-$118.00 after having opened the day at $109.40 as compared to the previous trading day's close of $109.54.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. Valeant Pharmaceuticals International has a market cap of $37.7 billion and is part of the drugs industry. Shares are down 23.5% year-to-date as of the close of trading on Tuesday. Currently there are 8 analysts who rate Valeant Pharmaceuticals International a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates

Valeant Pharmaceuticals International

as a

hold

. Among the primary strengths of the company is its robust revenue growth -- not just in the most recent periods but in previous quarters as well. At the same time, however, we also find weaknesses including a generally disappointing performance in the stock itself and unimpressive growth in net income. Get the full

Valeant Pharmaceuticals International Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care

(

RXD

).